Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005 a family of psilocin analogs. The company also develops MYCO-006 a family of MDMA analogs and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceut...
